Corpus ID: 53630489

Industry Testing of Opioids for Differential Schedule Control Purposes: Abuse-Deterrent Formulations

@inproceedings{Gauvin2016IndustryTO,
  title={Industry Testing of Opioids for Differential Schedule Control Purposes: Abuse-Deterrent Formulations},
  author={D. Gauvin and Zachary J Zimmermann and J. Theodore and H S Baird},
  year={2016}
}
Drug deterrence should not be viewed as “abuse proof” or “diversion proof”. If the abuse deterrent formulation (ADF) provides for a Cmax and half-life of parent compound that is conducive to maintain plasma opiate levels or abate drug withdrawal then compromising of the drug deterrence formulation seems irrelevant to the majority of street consumers those that consume an opiate outside the scope of medical practice. It is an error in judgment to think that all opiate dependent street… Expand

Figures from this paper

References

SHOWING 1-10 OF 59 REFERENCES
Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain.
  • 42
Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
  • 418
  • PDF
Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond
  • X. Ruan
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2011
  • 8
Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
  • 200
  • PDF
Opioid formulations in development designed to curtail abuse: who is the target?
  • 28
Current approaches in tamper-resistant and abuse-deterrent formulations
  • 49
Fentanyl patches: preventable overdose.
  • Medicine
  • Prescrire international
  • 2010
  • 4
...
1
2
3
4
5
...